



Contacts:

Accuri Cytometers:
Jennifer A. Baird
Chief Executive Officer
(734) 994-8000

Media:
Barbara Lindheim
GendeLLindheim BioCom Partners
(212) 918-4650

**ACCURI CYTOMETERS ANNOUNCES COMPLETION OF
\$5 MILLION SERIES B FINANCING LED BY BAIRD VENTURE PARTNERS**

Ann Arbor, MI - April 16, 2007 – Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a \$5 million Series B financing led by Baird Venture Partners (BVP), the U.S.-based venture capital fund of Baird Private Equity. Arboretum Ventures of Ann Arbor co-led the financing. Both firms are new investors in Accuri, which intends to use the Series B proceeds for the ongoing testing and upcoming commercial launch of the Accuri C6 Flow Cytometer™ System. Pete Shagory of BVP and Tim Petersen of Arboretum will join the company's Board of Directors.

Explicitly designed for routine use by biomedical researchers in their own labs, Accuri's flow cytometer system is a full featured benchtop cell analysis system that provides capabilities comparable to industry-leading flow cytometers in a more user-friendly format and at a fraction of the cost.

"Scientific advances increasingly rely on sophisticated tools such as flow cytometry, yet most researchers today only have limited access to centralized or shared flow cytometer instruments," said Pete Shagory, a Partner at Baird Venture Partners. "Accuri's high performance flow cytometer systems have the potential to accelerate and broaden the scope of biomedical research by making this technology more affordable, accessible and usable than ever before. We are extremely pleased to lead this investment in Accuri and support the company as it moves toward commercialization of its revolutionary flow cytometry technology."

"As neighbors in Ann Arbor who are focused on innovative technology, Arboretum is delighted to be co-leading the Series B financing for Accuri," said Tim Petersen, Managing Director at Arboretum Ventures. "Accuri has assembled an outstanding and diverse team of largely local talent to completely re-design the analytical flow cytometer from the ground up. Accuri is an excellent illustration of how the resources for innovation resident here in Michigan can be harnessed to produce highly novel products with great scientific and commercial potential. We look forward to supporting Accuri as they advance towards commercial launch of the Accuri flow cytometer system."

Accuri's product concept is based on the input of hundreds of researchers who use flow cytometry, including many whose research has been impacted by resource constraints in centralized core facilities. The resulting C6 Flow Cytometer System is compact, powerful and easy to maintain, while also being affordable by most individual research labs. A critical element of the Accuri approach is its user-friendly software, CFlow™, which is easy to use and quick to learn.

"We are receiving positive feedback from early beta customers who are helping us refine the system to ensure that we are delivering on the performance standards, quality and ease-of-use

that are central to our mission,” said Jennifer Baird, Chief Executive Officer of Accuri. “This critical round of funding will carry Accuri through broader beta testing and position us for full commercial launch next year. Both BVP and Arboretum Ventures bring extensive resources and experience in helping build early stage, entrepreneurial life sciences companies and we welcome their support and guidance as we move forward.”

For a limited time, Accuri is conducting beta tests of the Accuri C6 Flow Cytometer System with selected users. For more information about this program or about Accuri and the C6 Flow Cytometer series, visit www accuricytometers.com.

About Baird Venture Partners

Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes investments in early- to growth-stage companies in the Business Services and Healthcare/Life Sciences sectors. Baird Venture Partners leverages its in-depth sector knowledge, experienced investment team and network of relationships to serve as a value-added partner for its portfolio companies. For more information, please visit www.bairdventurepartners.com.

Baird Private Equity, the global private equity group affiliated with Robert W. Baird & Co. (Baird), makes venture capital, change-in-control and growth equity investments in the United States through Baird Venture Partners and Baird Capital Partners and in Europe through Baird Capital Partners Europe and Granville Baird Ltd, an affiliated fund manager that invests in Germany. With more than 40 investment professionals in the United States and Europe and over 20 operating professionals in Asia, Baird Private Equity has raised and managed \$1.8 billion in capital. Baird Private Equity’s operating resources in China and India, located in four offices, focus on facilitating and executing Asia sourcing, manufacturing and distribution opportunities for portfolio companies. The group’s investments are supported by Baird’s full range of financial advice, operating expertise and industry research, providing a unique full-service approach to the entire private equity investment process.

About Arboretum Ventures

Located in Ann Arbor, Arboretum Ventures is an early-stage venture capital firm that invests in private healthcare and life sciences companies. Our areas of focus include the medical device, medical equipment, diagnostic and healthcare service sectors. Arboretum takes pride in a hands-on, constructive approach to assisting our portfolio companies, born from our own experience in startups. We combine this entrepreneurial experience with a set of key relationships within the healthcare and medical technology industries. As a result, we help entrepreneurs develop valuable businesses, leading to outstanding returns for both our entrepreneurs and investors. Web site: www.arboretumvc.com.

About Accuri Cytometers

Accuri Cytometers Inc. is an Ann-Arbor based life sciences company developing revolutionary high performance cell analysis systems designed to bring the power of flow cytometry into the labs of life sciences researchers everywhere. Reflecting the input of hundreds of researchers, the Accuri C6 Flow Cytometer™ is a full featured benchtop cell analysis system that provides all of the capabilities of industry-leading flow cytometers in an easy-to-use format and at a fraction of their cost. The Accuri system was engineered from the start to be compact, powerful and user-friendly, while also being affordable by most research laboratories. The Accuri C6 Flow Cytometer System is currently in beta testing. For more information, visit www accuricytometers.com.